Notoginsenoside Ft1

Notoginsenoside Ft1
Product Name Notoginsenoside Ft1
CAS No.: 155683-00-4
Catalog No.: CFN90859
Molecular Formula: C47H80O17
Molecular Weight: 917.2 g/mol
Purity: >=98%
Type of Compound: Triterpenoids
Physical Desc.: Powder
Targets: p38MAPK | ERK | JNK | p21 | Bcl-2/Bax | Caspase | JAK | PI3K | Akt | NOS | NO | Estrogen receptor | cAMP | Calcium Channel | Calcium Channel | MEK | Raf | mTOR | HIF | VEGFR | Progestogen receptor
Source: The roots of Panax notoginseng
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Price: $118/20mg
Notoginsenoside Ft1 is a novel stimulator of angiogenesis, it stimulates angiogenesis via HIF-1α-mediated VEGF expression, with PI3K/AKT and Raf/MEK/ERK signaling cascades concurrently participating in the process; it has the potential therapeutic effect on human neuroblastoma, it can arrest the proliferation and elicited the apoptosis of SH-SY5Y cells possibly via p38 MAPK and ERK1/2 pathways.Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. Notoginsenoside Ft1 also provides a great potential application of it in clinics for patients with diabetic foot ulcers, it may accelerate diabetic wound healing by orchestrating multiple processes, including promoting fibroblast proliferation, enhancing angiogenesis, and attenuating inflammatory response.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Exp Biol Med (Maywood).2019, 244(16):1463-1474
  • Microbiol. Biotechnol. Lett.2022, 50(2): 193-201.
  • Front Aging Neurosci.2019, 11:230
  • Pharmaceuticals (Basel).2024, 17(3):352.
  • Front Microbiol.2023, 14:1232039.
  • Curr Top Med Chem.2020, 20(21):1898-1909.
  • Korean Journal of Pharmacognosy2017, 48(4):320-328
  • University of Guelph2021, 12.
  • Molecules.2020, 25(23):5609.
  • Br J Pharmacol.2016, 173(2):396-410
  • 20(S)-Ginsenoside Rh2

    Catalog No: CFN99971
    CAS No: 78214-33-2
    Price: $40/20mg
    20(R)-Ginsenoside Rh2

    Catalog No: CFN90340
    CAS No: 112246-15-8
    Price: $70/20mg
    12-Methoxyginsenoside Rh2

    Catalog No: CFN95749
    CAS No: N/A
    Price: $318/10mg
    Ginsenoside Rg3

    Catalog No: CFN99969
    CAS No: 14197-60-5
    Price: $40/20mg
    20(R)-Ginsenoside Rg3

    Catalog No: CFN98170
    CAS No: 38243-03-7
    Price: $60/20mg
    12-Methoxyginsenoside Rg3

    Catalog No: CFN95750
    CAS No: N/A
    Price: $318/5mg
    25-Methoxyginsenoside Rg3

    Catalog No: CFN95748
    CAS No: 2977279-15-3
    Price: $318/5mg
    20-Methoxyginsenoside Rg3

    Catalog No: CFN95763
    CAS No: N/A
    Price: $318/10mg
    Ginsenoside Rs3

    Catalog No: CFN92813
    CAS No: 194861-70-6
    Price: Inquiry(manager@chemfaces.com)
    Notoginsenoside Ft1

    Catalog No: CFN90859
    CAS No: 155683-00-4
    Price: $118/20mg
    Life Sci. 2014 Jul 17;108(2):63-70.
    p38 MAPK and ERK1/2 pathways are involved in the pro-apoptotic effect of notoginsenoside Ft1 on human neuroblastoma SH-SY5Y cells.[Pubmed: 24857982 ]
    This study aims to investigate the effect and the mechanisms of Notoginsenoside Ft1, a natural compound exclusively found in P. notoginseng, on the proliferation and apoptosis of human neuroblastoma SH-SY5Y cells.
    METHODS AND RESULTS:
    CCK-8 assay was used to assess the cell proliferation. Flow cytometry was performed to measure the cell cycle distribution and cell apoptosis. Hoechst 33258 staining was conducted to confirm the morphological changes of apoptotic cells. Protein expression was detected by western blot analysis and caspase 3 activity was measured by colorimetric assay kit. Among the saponins examined, Ft1 showed the best inhibitory effect on cell proliferation of SH-SY5Y cells with IC50 of 45μM. Ft1 not only arrested the cell cycle at S, G2/M stages, but also promoted cell apoptosis, which was confirmed by Hoechst 33258 staining. Further studies demonstrated that Ft1 up-regulated the protein expressions of cleaved caspase 3, phospho-p53, p21, and cyclin B1, but down-regulated that of Bcl-2. Moreover, Ft1 enhanced the phosphorylation of ERK1/2, JNK and p38 MAPK. However, the phosphorylation of Jak2 and p85 PI3K was reduced by Ft1. Inhibitors of p38 MAPK and ERK1/2 but not JNK abrogated the up-regulated protein expressions of cleaved caspase 3, p21 and down-regulated protein expression of Bcl-2 as well as elevated caspase 3 activity induced by Ft1.
    CONCLUSIONS:
    Ft1 arrested the proliferation and elicited the apoptosis of SH-SY5Y cells possibly via p38 MAPK and ERK1/2 pathways, which indicates the potential therapeutic effect of it on human neuroblastoma.
    Biochem Pharmacol. 2014 Mar 1;88(1):66-74.
    Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries.[Pubmed: 24440742]
    Panax notoginseng (Burk.) F.H. Chen has been used traditionally for the treatment of cardiovascular diseases. Notoginsenoside Ft1 (Ft1) is a bioactive saponin from the leaves of P. notoginseng. Experiments were designed to determine whether or not Ft1 is an endothelium-dependent vasodilator.
    METHODS AND RESULTS:
    Rat mesenteric arteries were suspended in organ chambers for the measurement of isometric tension during phenylephrine-induced contractions. The cyclic guanosine monophosphate (cGMP) level was assessed using enzyme immunoassay. The phosphorylation and protein expressions of endothelial nitric oxide synthase (eNOS), glucocorticoid receptors (GR), estrogen receptors beta (ERß), protein kinase B (Akt) and extracellular signal-regulated kinase 1/2 (ERK1/2) were determined by Western blotting. The localization of GR and ERß were determined by immunofluorescence staining. Ft1 caused endothelium-dependent relaxations, which were abolished by l-NAME (inhibitor of nitric oxide synthases) and ODQ (inhibitor of soluble guanylyl cyclase). Ft1 increased the cGMP level in rat mesenteric arteries. GR and ERß were present in the endothelial layer and their antagonism by RU486 and PHTPP, respectively, inhibited Ft1-induced endothelium-dependent relaxations and phosphorylations of eNOS, Akt and ERK1/2. Inhibition of phosphoinositide-3-kinase (PI3K) by wortmannin and ERK1/2 by U0126 reduced Ft1-evoked relaxations and eNOS phosphorylation.
    CONCLUSIONS:
    Taken in conjunction, the present findings suggest that Ft1 stimulates endothelial GRs and ERßs with subsequent activation of the PI3K/Akt and ERK1/2 pathways in rat mesenteric arteries. This results in phosphorylation of eNOS and the release of NO, which activates soluble guanylyl cyclase in the vascular smooth muscle cells leading to relaxations.
    J Pharmacol Exp Ther. 2016 Feb;356(2):324-32.
    Notoginsenoside Ft1 Promotes Fibroblast Proliferation via PI3K/Akt/mTOR Signaling Pathway and Benefits Wound Healing in Genetically Diabetic Mice.[Pubmed: 26567319]
    Wound healing requires the essential participation of fibroblasts, which is impaired in diabetic foot ulcers (DFU). Notoginsenoside Ft1 (Ft1), a saponin from Panax notoginseng, can enhance platelet aggregation by activating signaling network mediated through P2Y12 and induce proliferation, migration, and tube formation in cultured human umbilical vein endothelial cells. However, whether it can accelerate fibroblast proliferation and benefit wound healing, especially DFU, has not been elucidated.
    METHODS AND RESULTS:
    In the present study on human dermal fibroblast HDF-a, Ft1 increased cell proliferation and collagen production via PI3K/Akt/mTOR signaling pathway. On the excisional wound splinting model established on db/db diabetic mouse, topical application of Ft1 significantly shortened the wound closure time by 5.1 days in contrast with phosphate-buffered saline (PBS) treatment (15.8 versus 20.9 days). Meanwhile, Ft1 increased the rate of re-epithelialization and the amount of granulation tissue at day 7 and day 14. The molecule also enhanced mRNA expressions of COL1A1, COL3A1, transforming growth factor (TGF)-β1 and TGF-β3 and fibronectin, the genes that contributed to collagen expression, fibroblast proliferation, and consequent scar formation. Moreover, Ft1 facilitated the neovascularization accompanied with elevated vascular endothelial growth factor, platelet-derived growth factor, and fibroblast growth factor at either mRNA or protein levels and alleviated the inflammation of infiltrated monocytes indicated by reduced tumor necrosis factor-α and interleukin-6 mRNA expressions in the diabetic wounds.
    CONCLUSIONS:
    Altogether, these results indicated that Ft1 might accelerate diabetic wound healing by orchestrating multiple processes, including promoting fibroblast proliferation, enhancing angiogenesis, and attenuating inflammatory response, which provided a great potential application of it in clinics for patients with DFU.
    Br J Pharmacol. 2014 Jan;171(1):214-23.
    Platelet P2Y₁₂ receptors are involved in the haemostatic effect of notoginsenoside Ft1, a saponin isolated from Panax notoginseng.[Pubmed: 24117220 ]
    Among the saponins examined, Notoginsenoside Ft1 was the most potent procoagulant and induced dose-dependent platelet aggregation.
    METHODS AND RESULTS:
    Notoginsenoside Ft1 reduced plasma coagulation indexes, decreased tail bleeding time and increased thrombogenesis. Moreover, it potentiated ADP-induced platelet aggregation and increased cytosolic Ca(2+) accumulation, effects that were attenuated by clopidogrel. Molecular docking analysis suggested that Notoginsenoside Ft1 binds to platelet P2Y₁₂ receptors. The increase in intracellular Ca(2+) evoked by Notoginsenoside Ft1 in HEK293 cells overexpressing P2Y₁₂ receptors could be blocked by ticagrelor. Notoginsenoside Ft1 also affected the production of cAMP and increased phosphorylation of PI3K and Akt downstream of P2Y₁₂ signalling pathways.
    CONCLUSIONS:
    Notoginsenoside Ft1 enhanced platelet aggregation by activating a signalling network mediated through P2Y₁₂ receptors. These novel findings may contribute to the effective utilization of this compound in the therapy of haematological disorders.
    Biochem Pharmacol. 2012 Sep 15;84(6):784-92.
    Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways.[Pubmed: 22771629]
    Notoginsenoside Ft1 (Ft1) is a saponin isolated from Panax notoginseng, which has been used traditionally for the treatment of trauma injuries in East Asia.
    METHODS AND RESULTS:
    Here we show that Ft1 is a novel stimulator of angiogenesis. The results show that Ft1 induces proliferation, migration, and tube formation in cultured human umbilical vein endothelial cells (HUVECs). Ft1 increases translocalization of hypoxia-inducible factor-1α (HIF-1α) from cytoplasm to nuclei, where it binds to the vascular endothelial growth factor (VEGF) promoter, increasing the expression of VEGF mRNA and the subsequent secretion of the growth factor. Ft1 induces the activation of PI3K/AKT and Raf/MEK/ERK signaling pathways. Pharmacological inhibition with LY294002, wortmanin or PD98059 reduces Ft1-induced angiogenesis, indicating the important role played by these pathways. In addition, Ft1 induces phosphorylation of the mammalian target of rapamycin (mTOR), and siRNA-mediated mTOR knockdown decreases tube formation, proliferation, transport of HIF-1α into nuclei and VEGF mRNA expression in response to Ft1. Finally, in vivo, Ft1 promotes the formation of blood vessels in Matrigel plug and wound healing in mice.
    CONCLUSIONS:
    Taken together, the present results reveal that Ft1 stimulates angiogenesis via HIF-1α-mediated VEGF expression, with PI3K/AKT and Raf/MEK/ERK signaling cascades concurrently participating in the process.
    3''-O-Galloylmyricitrin

    Catalog No: CFN95057
    CAS No: 143202-36-2
    Price: $333/5mg
    (3E,5E,11E)-tridecatriene-7,9-diyne-1,2-diacetate

    Catalog No: CFN95191
    CAS No: 94753-06-7
    Price: $318/5mg
    Spinacetin

    Catalog No: CFN95194
    CAS No: 3153-83-1
    Price: $318/5mg
    Arisanschinin E

    Catalog No: CFN95221
    CAS No: 1333378-33-8
    Price: Inquiry(manager@chemfaces.com)
    15-Methoxy-16-oxo-15,16H-strictic acid

    Catalog No: CFN95261
    CAS No: 1356388-38-9
    Price: $368/5mg
    Grosvenorin 2''-glucoside

    Catalog No: CFN95282
    CAS No: N/A
    Price: $318/5mg
    10-O-trans-p-coumaroylscandoside

    Catalog No: CFN95391
    CAS No: 870785-25-4
    Price: $318/10mg
    Murracarpin

    Catalog No: CFN95409
    CAS No: 120786-76-7
    Price: $413/5mg
    5-O-Coumaroylquinic acid

    Catalog No: CFN95507
    CAS No: 32451-86-8
    Price: $318/5mg
    Mahuannin E

    Catalog No: CFN95585
    CAS No: 1173887-70-1
    Price: $318/5mg